Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$891.07 USD

891.07
1,725,135

+6.59 (0.75%)

Updated Oct 2, 2024 04:00 PM ET

After-Market: $891.10 +0.03 (0.00%) 7:12 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 17% (44 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Bayer (BAYRY) Beats on Q3 Earnings, Revenue Estimates

Bayer (BAYRY) surpasses earnings and sales estimates in the third quarter of 2018 and reiterates outlook for 2018.

Eli Lilly (LLY) Gains As Market Dips: What You Should Know

Eli Lilly (LLY) closed at $113.20 in the latest trading session, marking a +0.88% move from the prior day.

AVEO Pharmaceuticals (AVEO) Q3 Earnings & Revenues Top Mark

AVEO Pharmaceuticals' (AVEO) loss is narrower than estimated in the third quarter. Also, the company???s revenues beat estimates.

Catalyst (CPRX) Reports Q3 Loss as Expected & Pipeline Update

Catalyst (CPRX) provides pipeline update and the FDA sets action date of Nov 28, 2018 for its lead pipeline candidate, Firdapse during the third quarter of 2018.

Keryx's (KERX) Loss Narrower Than Expected in Q3, Sales Lag

Keryx's (KERX) sole marketed product generates sales of $26.6 million in the third quarter, up 96% from the year-ago quarter.

Celldex (CLDX) Q3 Earnings Beat Estimates, Revenues Miss

Celldex (CLDX) reports narrower-than-expected loss in Q3. Revenues fall on reduced contract revenues and also miss estimates.

Pharma Stock Roundup: LLY, AZN Report Q3 Earnings, PFE Gets FDA Nod for Cancer Drug

Lilly (LLY) and AstraZeneca (AZN) report third-quarter results. Pfizer (PFE) gains FDA approval for a new cancer medicine.

Horizon Pharma (HZNP) Q3 Earnings & Sales Beat, Shares Rise

Shares of Horizon Pharma (HZNP) rise almost 16%, owing to record quarterly sales during the third quarter of 2018.

Nektar (NKTR) Q3 Earnings & Sales Beat Estimates, Shares Up

Nektar's (NKTR) earnings and sales beat estimates in the third quarter. The company enters oncology clinical collaboration with Pfizer to evaluate NKTR-214 combination therapy.

AstraZeneca's (AZN) Q3 Earnings Beat, New Drugs Drive Sales

AstraZeneca (AZN) beats earnings and sales estimates in the third quarter and maintains previously issued outlook for 2018. AstraZeneca's newer medicines sales rise 86% in the quarter.

Mallinckrodt (MNK) Beats on Q3 Earnings Estimates, Ups View

Mallinckrodt (MNK) surpasses both earnings and sales estimates in the third quarter of 2018.

Sanofi Eczema Drug Dupixent's sBLA Gets Priority Review

Sanofi (SNY) and partner Regeneron announce priority review to label expansion application of Dupixent seeking approval in adolescent patients with moderate-to-severe atopic dermatitis.

Amgen (AMGN) Counts on New Drugs Amid Rising Biosimilar Woes

Amgen's newer drugs, Prolia, Xgeva, Kyprolis, are driving sales. Lower sales of mature drugs like Enbrel and biosimilar competition for Neulasta/Epogen are concerns.

Ryan McQueeney headshot

Will Stocks Gain After the Elections? & Earnings from CVS, LLY, HEAR

Ryan McQueeney chats with Dave Bartosiak about the near-term outlook for stocks after the midterm elections and the earnings outlook for Turtle Beach ahead of its report. The host also recaps earnings results from CVS, Eli Lilly, and Regeneron.

September JOLTS Report In Spotlight

September JOLTS Report In Spotlight

Mark Vickery headshot

Playing the Waiting Game; Plus MedTech, Pharma in Q3 Earnings

We won't get the final numbers until later, so until then we're just playing the waiting game.

Lilly (LLY) Tops Q3 Earnings, Lifts 2018 Outlook, Stock Up

Eli Lilly (LLY) beats estimates for earnings but misses the same for sales. The company raises its previously issued outlook for adjusted earnings. Stock rises in pre-market trading.

Eli Lilly (LLY) Q3 Earnings Surpass Estimates

Lilly (LLY) delivered earnings and revenue surprises of 1.46% and -0.70%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Epizyme (EPZM) Reports Narrower-Than-Expected Loss in Q3

Epizyme (EPZM) incurs narrower-than-expected loss in the third quarter of 2018. The company is on track to submit an NDA for tazemetostat in epithelioid sarcoma in the first half of 2019.

Is Eli Lilly and (LLY) Stock Outpacing Its Medical Peers This Year?

Is (LLY) Outperforming Other Medical Stocks This Year?

Disney, Michael Kors, Ralph Lauren and Eli Lilly are part of Zacks Earnings Preview

Disney, Michael Kors, Ralph Lauren and Eli Lilly are part of Zacks Earnings Preview

Shire's (SHPG) Earnings, Revenues Miss Estimates in Q3

Shire (SHPG) misses earnings and revenue estimates in the third quarter of 2018. The company completes the sale of its Oncology franchise in the quarter.

AMAG Posts Wider-Than-Expected Q3 Loss, Beats on Revenues

AMAG reports wider than expected loss in the third quarter of 2018. The company completed the sale of Cord Blood Registry in August 2018.

Radius Health (RDUS) Posts Narrower-Than-Expected Q3 Loss

Radius Health (RDUS) posts narrower Q3 loss as Tymlos sales gains traction.

Teva (TEVA) Q3 Earnings Beat, 2018 EPS View Up, Shares Rise

Teva's (TEVA) shares up 15% despite mixed third-quarter results as it increases its earnings and free cash flow guidance for the full year.